Immediate Impact
2 from Science/Nature 58 standout
Citing Papers
Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Works of Ayako Ojima being referenced
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
2015
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ayako Ojima | 259 | 390 | 238 | 17 | 740 | |
| Nobutaka Nakamura | 347 | 389 | 192 | 19 | 829 | |
| Yuri Nishino | 330 | 427 | 194 | 25 | 874 | |
| Mamoru Ikemoto | 333 | 212 | 321 | 14 | 949 | |
| Motofumi Sasaki | 104 | 325 | 200 | 16 | 759 | |
| Atsuko Abiko | 90 | 331 | 284 | 26 | 780 | |
| Despina Tsorotes | 175 | 221 | 330 | 12 | 877 | |
| Kohachiro Koga | 568 | 286 | 214 | 11 | 931 | |
| Hirofumi Shigeta | 195 | 191 | 181 | 24 | 679 | |
| Akira Mima | 134 | 145 | 307 | 19 | 889 | |
| Hiromi Fujishima | 151 | 374 | 256 | 12 | 986 |
All Works
Loading papers...